Longer wait times after ED-initiated buprenorphine associated with lower appointment attendance

Background Buprenorphine, a medication for opioid use disorder, improves patient outcomes, and emergency department induction of buprenorphine (EDIB) offers a low-barrier entry to treatment. While longer intervals between referral and first outpatient appointment in non-ED settings are known to decrease attendance, the effect of the interval between EDIB and first outpatient follow-up has not been established. Objectives To examine how the wait time between EDIB and the first outpatient appointment for medication for opioid use disorder (MOUD) affects attendance at that initial visit. We tested the null hypothesis that wait time is not associated with attendance. Methods In this single-center retrospective cohort study, data were collected on adult ED patients who received EDIB (observed induction) or a buprenorphine prescription only (unobserved induction) between July 1, 2019, and December 31, 2025. Follow-up appointment attendance was obtained from referral centers. Chi-square, Fisher's exact, and Mann-Whitney U tests were used to compare attendance across demographic variables. Multivariable logistic regression estimated the adjusted odds ratio (AOR) of appointment attendance, controlling for demographics, insurance status, buprenorphine formulation, induction type, primary opioid, and polysubstance use. A Kaplan-Meier curve illustrated the relationship between appointment attendance and wait time. Results Of the 301 included individuals (65.4% male, 74.8% white, 30.9% insured), 51.2% attended the follow-up appointment. No associations were observed with demographics, substance use factors, or buprenorphine administration characteristics (all p > 0.05). Each additional day of wait time increased the odds of non-attendance by 31% (AOR = 1.310, 95% CI 1.099–1.560). The wait time at which attendance probability reached 50% was 3 days (95% CI 2.493–3.507). Conclusions A shorter wait time from EDIB to the first outpatient follow-up appointment is associated with increased appointment attendance. This study was limited to a single ED and may not be generalizable to all EDIB programs.

Authors

Institutions

Publication Details

Journal
The American Journal of Emergency Medicine
Published
2026-11-13
DOI
https://doi.org/10.1016/j.ajem.2026.11.021
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Longer wait times after ED-initiated buprenorphine associated with lower appointment attendance

Louise F. Haynes, Kelly Stephenson Barth, Kathleen T. Brady, Lindsey K. Jennings et al.
1 links
The American Journal of Emergency Medicine
Opioid Use Disorder Treatment
article

Longer wait times after ED-initiated buprenorphine associated with lower appointment attendance

Louise F. Haynes, Kelly Stephenson Barth, Kathleen T. Brady, Lindsey K. Jennings, Sarah S. Gainey, Suzanne Lane, Alexandra Aven
article en

Abstract

Background Buprenorphine, a medication for opioid use disorder, improves patient outcomes, and emergency department induction of buprenorphine (EDIB) offers a low-barrier entry to treatment. While longer intervals between referral and first outpatient appointment in non-ED settings are known to decrease attendance, the effect of the interval between EDIB and first outpatient follow-up has not been established. Objectives To examine how the wait time between EDIB and the first outpatient appointment for medication for opioid use disorder (MOUD) affects attendance at that initial visit. We tested the null hypothesis that wait time is not associated with attendance. Methods In this single-center retrospective cohort study, data were collected on adult ED patients who received EDIB (observed induction) or a buprenorphine prescription only (unobserved induction) between July 1, 2019, and December 31, 2025. Follow-up appointment attendance was obtained from referral centers. Chi-square, Fisher's exact, and Mann-Whitney U tests were used to compare attendance across demographic variables. Multivariable logistic regression estimated the adjusted odds ratio (AOR) of appointment attendance, controlling for demographics, insurance status, buprenorphine formulation, induction type, primary opioid, and polysubstance use. A Kaplan-Meier curve illustrated the relationship between appointment attendance and wait time. Results Of the 301 included individuals (65.4% male, 74.8% white, 30.9% insured), 51.2% attended the follow-up appointment. No associations were observed with demographics, substance use factors, or buprenorphine administration characteristics (all p > 0.05). Each additional day of wait time increased the odds of non-attendance by 31% (AOR = 1.310, 95% CI 1.099–1.560). The wait time at which attendance probability reached 50% was 3 days (95% CI 2.493–3.507). Conclusions A shorter wait time from EDIB to the first outpatient follow-up appointment is associated with increased appointment attendance. This study was limited to a single ED and may not be generalizable to all EDIB programs.

The American Journal of Emergency MedicineVol. 112
Medical University of South Carolina (US)
Good health and well-being
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon